

Round 1

Response to reviewers

Manuscript NO.: 55011, Minireviews

Dear Editor,

We have addressed all issues raised in the peer-review report in the revised manuscript, with modified text marked in red font. We reply to the reviewer's specific comments point-by-point below:

Reviewer #1:

In this review the authors summarized the factors that predict whether a patient with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) will successfully achieve treatment free remission (TFR), that is, if they can successfully discontinue treatment without relapsing. The topic is interesting, however the review lacks of figures and/or tables that could help the readers to follow the text.

Two tables are included in this review.

Sometimes the paragraphs are not well distinguished among them and seem a repetition of each other.

We have divided the text on "Prognostic variables for TFR" into numbered subheadings to help distinguish between the paragraphs.

In the introduction few information should be added regarding CML before introducing the FDA treatment. Few information should be also given about tyrosine kinases and their inhibitors (TKI).

We have added to the Introduction two paragraphs on CML and one paragraph on TKIs (page 3) as requested by the reviewer.

Predictive indicators of successful TKI discontinuation in patients with chronic myeloid leukemia, as stated in the title, should be clearly underlined in the conclusion part of the review.

A paragraph has been added to the Conclusion (page 15) to summarize the predictive indicators, as suggested by the reviewer.

EDITORIAL OFFICE'S COMMENTS

Conflict-of-Interest Disclosure Form is not qualified.

The signed COI form has been uploaded.

(b) Requirements for tables: Please provide decomposable Tables (whose parts are all movable and editable), organize them into a single Word file, and submit as "55011-Tables.docx" on the system. The tables should be uploaded to the file destination of "Table File".

A single Tables file has been uploaded.

Please click and download the Copyright License Agreement Form. Subsequently, a PDF (scanned) version of the Copyright License Agreement Form that has been signed by all authors should be uploaded to the file destination of 'Copyright License Agreement'.

The Copyright License Agreement form has been signed and uploaded.

We hope this Mini-Review is now accepted for publication.

Sincerely

Dr. María Teresa Gómez Casares

Corresponding author

University Hospital of Gran Canaria Dr. Negrín

Las Palmas, Spain

Round 2

Response to reviewers

Manuscript NO.: 55011, Minireviews

Dear Editor,

We have addressed the final remaining issues raised by the reviewer. The changes appear in the revised manuscript in red text (ATTACHED). We reply to the reviewer's comments point-by-point below: The authors have addressed the reviewer's comments and improved the quality of the manuscript. Still some points need to be amended:

1、 In the introduction please add abbreviation "CML": "Chronic myeloid leukemia (CML) is a neoplasia of the pluripotent hematopoietic progenitor cells characterized by the clonal expansion..."

- Abbreviation CML added.

2、 In general check if all the abbreviation have been extensively explained at first appearance. -MMR defined on page 10. All other abbreviations checked. Please define MPNs : ..."molecular basis of the MPNs".

-MPNs defined.

3、 Please add references: "CML is defined by the presence of a reciprocal translocation between chromosomes 9 and 22 t(9;22)(q34;q11), resulting in a shortened chromosome 22 known as the Philadelphia chromosome, which leads to the expression of the fusion oncogene BCR-ABL1 encoding a constitutively active tyrosine kinase".

-Reference added.

4、 "Imatinib mesylate (Gleevec®) was the first tyrosine kinase inhibitor (TKI) developed to specifically target the BCR-ABL1 oncoprotein. Physicians now have five approved TKIs available for the treatment of patients with CML: dasatinib (Sprycel), nilotinib (Tasigna), and bosutinib (Bosulif) for first- or second-line therapy and ponatinib (Iclusig) for patients with resistance or intolerance to prior therapy".

-Reference added.

We hope this Mini-Review can now proceed to publication.

Sincerely Dr. María Teresa Gómez Casares Corresponding author University
Hospital of Gran Canaria Dr. Negrín Las Palmas, Spain